PTH bioactivity in osteoporosis
Abstract
The cytochemical bioassay for parathyroid hormone was used to measure the levels of PTH bioactivity in normal elderly subjects and patients suffering from idiopathic or postmenopausal osteoporosis. In normal subjects, PTH bioactivity did not increase with age. In the osteoporotic patients levels of bioPTH discriminated between two populations, one with normal levels and the other with elevated levels. In both these groups the PTH bioactivity was neutralised by the addition of a PTH antiserum. The recovery of the bioactivity of PTH added to the plasma samples was significantly higher in the plasmas from patients with elevated levels of bioPTH. Levels of immunoreactive PTH also discriminated between the two groups of osteoporotic patient although no serum parameters indicative of increased PTH were detectable. However, patients with the high levels of bio- and immunoPTH had a lower incidence of fracture within the previous 12 months.
Read the paper
Related studies
- Development of a crushable foam model for human trabecular bone
- Data-driven motion compensation in HR-pQCT.
- Modeling of structure, quality, and function in the orthodontic patient
- Exploring the mechanism of Heidihuang Pill in the treatment of osteoporosis based on network pharmacology, molecular docking, and experimental validation
- Effect of fabric on the accuracy of computed tomography-based finite element analyses of the vertebra
- Use of interventions involving virtual reality tasks during the climacteric: a systematic review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.